Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Apr;73(7):872–876. doi: 10.1038/bjc.1996.155

Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth.

J A Lawson 1, W J Adams 1, D L Morris 1
PMCID: PMC2074256  PMID: 8611398

Abstract

Histamine has recently been shown to be a growth factor for some gastric and colorectal cancer cells. Previous studies have shown that cimetidine blocks in vitro and in vivo histamine-stimulated growth and cAMP release from the human colonic cancer cell line, C170. In this study, ranitidine, another H2 receptor antagonist, did not affect either basal or histamine-stimulated in vitro proliferation of C170, and failed to prevent cAMP release in vitro. Ranitidine did not inhibit in vivo growth of C170 at a dose of 1, 10, 25, 50 or 100 mg/kg, in contrast to 50 mg/kg/day cimetidine, which produced 39.3% inhibition of tumour volume (p<0.01) after 23 days' treatment. Ranitidine did not inhibit in vivo histamine-stimulated growth of C170 cells . LIM2412, another colonic cancer cell line, was significantly stimulated by both cimetidine and ranitidine in vivo. Ranitidine had no effect on in vitro cell proliferation.

Full text

PDF
872

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams W. J., Lawson J. A., Morris D. L. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut. 1994 Nov;35(11):1632–1636. doi: 10.1136/gut.35.11.1632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Adams W. J., Lawson J. A., Nicholson S. E., Cook T. A., Morris D. L. The growth of carcinogen-induced colon cancer in rats is inhibited by cimetidine. Eur J Surg Oncol. 1993 Aug;19(4):332–335. [PubMed] [Google Scholar]
  3. Allen J. I., Syropoulos H. J., Grant B., Eagon J. C., Kay N. E. Cimetidine modulates natural killer cell function of patients with chronic lymphocytic leukemia. J Lab Clin Med. 1987 Apr;109(4):396–401. [PubMed] [Google Scholar]
  4. Durrant L. G., Robins R. A., Pimm M. V., Perkins A. C., Armitage N. C., Hardcastle J. D., Baldwin R. W. Antigenicity of newly established colorectal carcinoma cell lines. Br J Cancer. 1986 Jan;53(1):37–45. doi: 10.1038/bjc.1986.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Emami S., Gespach C., Bodéré H. Selective disappearance of histamine H2-receptor activity in the human gastric cancer cell line HGT-1 after short-term or chronic treatment by histamine or its H2-antagonists. Agents Actions. 1985 Apr;16(3-4):195–198. doi: 10.1007/BF01983137. [DOI] [PubMed] [Google Scholar]
  6. Euhus D. M., Hudd C., LaRegina M. C., Johnson F. E. Tumor measurement in the nude mouse. J Surg Oncol. 1986 Apr;31(4):229–234. doi: 10.1002/jso.2930310402. [DOI] [PubMed] [Google Scholar]
  7. Gifford R. R., Tilberg A. F. Histamine type-2 receptor antagonist immune modulation. II. Cimetidine and ranitidine increase interleukin-2 production. Surgery. 1987 Aug;102(2):242–247. [PubMed] [Google Scholar]
  8. Hahm K. B., Kim W. H., Lee S. I., Kang J. K., Park I. S. Comparison of immunomodulative effects of the histamine-2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients. Scand J Gastroenterol. 1995 Mar;30(3):265–271. doi: 10.3109/00365529509093275. [DOI] [PubMed] [Google Scholar]
  9. Hellstrand K., Hermodsson S. Histamine H2-receptor-mediated regulation of human natural killer cell activity. J Immunol. 1986 Jul 15;137(2):656–660. [PubMed] [Google Scholar]
  10. Kikuchi Y., Oomori K., Kizawa I., Kato K. Effects of cimetidine on tumor growth and immune function in nude mice bearing human ovarian carcinoma. J Natl Cancer Inst. 1985 Feb;74(2):495–498. [PubMed] [Google Scholar]
  11. Kusyk C. J., McNiel N. O., Johnson L. R. Stimulation of growth of a colon cancer cell line by gastrin. Am J Physiol. 1986 Nov;251(5 Pt 1):G597–G601. doi: 10.1152/ajpgi.1986.251.5.G597. [DOI] [PubMed] [Google Scholar]
  12. Lin J. H. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet. 1991 Mar;20(3):218–236. doi: 10.2165/00003088-199120030-00004. [DOI] [PubMed] [Google Scholar]
  13. Matsumoto S. Cimetidine and survival with colorectal cancer. Lancet. 1995 Jul 8;346(8967):115–115. doi: 10.1016/s0140-6736(95)92136-2. [DOI] [PubMed] [Google Scholar]
  14. Nielsen H. J., Moesgaard F., Kehlet H. Ranitidine for prevention of postoperative suppression of delayed hypersensitivity. Am J Surg. 1989 Mar;157(3):291–294. doi: 10.1016/0002-9610(89)90553-9. [DOI] [PubMed] [Google Scholar]
  15. Nielsen H. J., Pedersen B. K., Moesgaard F., Haahr P. M., Kehlet H. Effect of ranitidine on postoperative suppression of natural killer cell activity and delayed hypersensitivity. Acta Chir Scand. 1989 Aug;155(8):377–382. [PubMed] [Google Scholar]
  16. Osband M. E., Hamilton D., Shen Y. J., Cohen E., Shlesinger M., Lavin P., Brown A., McCaffrey R. Successful tumour immunotherapy with cimetidine in mice. Lancet. 1981 Mar 21;1(8221):636–638. doi: 10.1016/s0140-6736(81)91554-3. [DOI] [PubMed] [Google Scholar]
  17. Seamon K. B., Daly J. W. Forskolin: a unique diterpene activator of cyclic AMP-generating systems. J Cyclic Nucleotide Res. 1981;7(4):201–224. [PubMed] [Google Scholar]
  18. Svendsen L. B., Ross C., Knigge U., Frederiksen H. J., Graversen P., Kjaergård J., Luke M., Stimpel H., Sparsø B. H. Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind, randomized pilot study. Dis Colon Rectum. 1995 May;38(5):514–518. doi: 10.1007/BF02148852. [DOI] [PubMed] [Google Scholar]
  19. Tutton P. J., Barkla D. H. Comparison of the tumor inhibiting effects of three histamine H2-receptor antagonists. Anticancer Res. 1983 Jan-Feb;3(1):7–10. [PubMed] [Google Scholar]
  20. Tønnesen H., Knigge U., Bülow S., Damm P., Fischerman K., Hesselfeldt P., Hjortrup A., Pedersen I. K., Pedersen V. M., Siemssen O. J. Effect of cimetidine on survival after gastric cancer. Lancet. 1988 Oct 29;2(8618):990–992. doi: 10.1016/s0140-6736(88)90743-x. [DOI] [PubMed] [Google Scholar]
  21. Watson S. A., Wilkinson L. J., Robertson J. F., Hardcastle J. D. Effect of histamine on the growth of human gastrointestinal tumours: reversal by cimetidine. Gut. 1993 Aug;34(8):1091–1096. doi: 10.1136/gut.34.8.1091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Whitehead R. H., Zhang H. H., Hayward I. P. Retention of tissue-specific phenotype in a panel of colon carcinoma cell lines: relationship to clinical correlates. Immunol Cell Biol. 1992 Aug;70(Pt 4):227–236. doi: 10.1038/icb.1992.30. [DOI] [PubMed] [Google Scholar]
  23. Whitehead R. J., Taylor D. J., Evanson J. M., Hart I. R., Woolley D. E. Demonstration of histamine H2 receptors on human melanoma cells. Biochem Biophys Res Commun. 1988 Feb 29;151(1):518–523. doi: 10.1016/0006-291x(88)90624-9. [DOI] [PubMed] [Google Scholar]
  24. Woodings E. P., Dixon G. T., Harrison C., Carey P., Richards D. A. Ranitidine--a new H2-receptor antagonist. Gut. 1980 Mar;21(3):187–191. doi: 10.1136/gut.21.3.187. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES